Prenetics Global Ltd (PRE) Stock AnalysisPREPrenetics Global Ltd

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8. It operates in the Healthcare sector (ACCIDENT & HEALTH INSURANCE industry).

Prenetics Global Ltd is a good buy right now due to its current price of $25.76, which is significantly below the average analyst price target of $37, indicating substantial upside potential. The company has shown remarkable growth with a year-to-date change of +63.24% and a one-year change of +216.07%. Additionally, the recent partnership with Lily Collins and raised revenue guidance to $220-$230 million for FY 2026 highlight strong market positioning and growth prospects. However, the main risk is the net loss of $23.1 million reported in Q1 2026, which could impact investor sentiment if not addressed.